ANALYSIS OF ASSOCIATIONS OF VEGF-A GENE POLYMORPHISM AT POSITIONS 2578A/C AND +936C/T WITH DIFFERENT RECEPTOR STATUS IN BREAST CANCER PATIENTS
Abstract
The study of functional polymorphism of the VEGF-A gene at positions –2578 in the promoter region and +936 in the 3`untranslated region in breast cancer patients with different receptor status of the tumor was undertaken to identify markers associated with risk of breast cancer. DNA samples from 292 women with breast cancer were analyzed. The genotyping of С–2578A and C+936T VEG-FA polymorphisms was performed using the method of restriction analysis of amplification products. The distributions of VEGF-A genotypes in patients having estrogen and progesterone receptors in tumor tissues were investigated and genotypes associated with risk of breast cancer recurrences were detected.
About the Authors
A. V. Shevchenko
Research Institute of Clinical and Experimental Lymphology, Novosibirsk
Russian Federation
Russian Federation
V. I. Konenkov
Research Institute of Clinical and Experimental Lymphology, Novosibirsk
Russian Federation
Russian Federation
N. N. Babyshkina
Cancer Research Institute, SB RAMS, Tomsk
Russian Federation
Russian Federation
O. V. Savenkova
Cancer Research Institute, SB RAMS, Tomsk
Russian Federation
Russian Federation
E. M. Slonimskaya
Cancer Research Institute, SB RAMS, Tomsk, Siberian State Medical University, Tomsk
Russian Federation
Russian Federation
References
1. Arias-Pulido H., Chaher N., Gong Y. et al. Tumor stromal vascular endothelial growth factor A is predictive of poor outcome in inflammatory breast cancer // BMC Cancer. 2012. Vol. 12. P. 298.
2. Bando H., Weich H., Brokelmann M. et al. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer // Br. J. Cancer. 2005. Vol. 92. P. 553–561.
3. Banyasz I., Szabo S., Bokodi G. et al. Genetic polymorphisms of vascular endothelial growth factor in severe preeclampsia // Mol. Hum. Reprod. 2006. Vol. 12. P. 233–236.
4. Bland J., Altman D. Education and debate. The odds ratio // BMJ. 2000. Vol. 320. P. 1468.
5. Carmeliet P., Jain R. Angiogenesis in cancer and other diseases // Nature. 2000. Vol. 407. P. 249–257.
6. Dabrosin C. Positive correlation between estradiol and vascular endothelial growth factor but not fibroblast growth factor-2 in normal human breast tissue in vivo // Clin. Cancer Res. 2005. Vol. 11. P. 8036–8041.
7. Gasparini G. Prognostic value of vascular endothelial growth factor in breast cancer // Oncologist. 2000. Vol. 5. P. 37–44.
8. Jakubowska A., Gronwald J., Menkiszak J. et al. The VEGF 936 C>T 3’UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women // Cancer Lett. 2007. Vol. 262 (1). P. 71–76.
9. Jin Q., Hemminki K., Enquist K. et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis // Clin. Cancer Res. 2005. Vol. 11. P. 3647–3653.
10. Kataoka N., Cai Q., Wen W. et al. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women // Cancer Epidemiol. Biomarkers Prev. 2006. Vol. 15. P. 1148–1152.
11. Kidd L., Brock G., Vancleave T. et al. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival // Cancer Caus. Contr. 2010. Vol. 21. P. 1545–1557.
12. Kim J., Oh D., Kwak S. et al. Genetic polymorphism of vascular endothelial growth factor (VEGF C936T) in the Korean population // Korean J. Biol. Sci. 2003. Vol. 7. P. 261–264.
13. Krippl P., Langsenlehner U., Renner W. et al. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk // Int. J. Cancer. 2003. Vol. 106. P. 468–471.
14. Lambrechts D., Storkebaum E., Morimoto M. et al. VEGF is a modifier of amyotrophic lateral sclerosis in mice and humans and protects motoneurons against ischemic death // Nat. Genet. 2003. Vol. 34. P. 383–394.
15. Linardou H., Kalogeras K.T., Kronenwett R. et al. The prognostic and predictive value of mRNA expression of vascular endothelial growth factor family members in breast cancer: a study in primary tumors of highrisk early breast cancer patients participating in a randomized Hellenic Cooperative Oncology Group trial // Breast Cancer Res. 2012. Vol. 14. P. 145.
16. Linderholm B.K., Lindh B., Beckman L. et al. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers // Clin. Breast Cancer. 2003. Vol. 4. P. 340–347.
17. Linderholm B., Lindh B., Tavelin B. et al. P53 and vascular-endothelialgrowth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma // Int. J. Cancer. 2000. Vol. 89. P. 51–62.
18. Maae E., Andersen R., Steffensen K. et al. Prognostic impact of VEGFA germline polymorphisms in patients with HER2-positive primary breast cancer // Anticancer Res. 2012. Vol. 32. P. 3619–3627.
19. Madeddy P. Therapeutic angiogenesis and vasculogenesis for tissue regeneration // Exp. Physiol. 2004. Vol. 90 (3). P. 315–326.
20. Oliveira C., Lourenço G., Silva P. et al. Polymorphisms in the 5’- and 3’-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics // Tumour Biol. 2011. Vol. 32. P. 295–300.
21. Perrot-Applanat M., Di Benedetto M. Autocrine functions of VEGF in breast tumor cells: Adhesion, survival, migration and invasion // Cell Adh. Migr. 2012. Vol. 6. P. 547–553.
22. Relf M., LeJeune S., Scott P. et al. Expression of the angiogenic factors vascular endothelial cell growth factor, acidic and basic fibroblast growth factor, tumor growth factor beta-1, platelet-derived endothelial cell growth factor, placenta growth factor, and pleiotrophin in human primary breast cancer and its relation to angiogenesis // Cancer Res. 1997. Vol. 57. P. 963–969.
23. Rodrigues P., Furriol J., Tormo E. et al. The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population // Breast Cancer Res. Treat. 2012. Vol. 133. P. 769–778.
24. Schneider B., Radovich M., Sledge G. et al. Association of polymorphisms
25. of angiogenesis genes with breast cancer // Breast Cancer Res. Treat. 2008. Vol. 111. P. 157–163.
26. Shahbazi M., Fryer A., Pravica V. et al. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection // J. Am. Soc. Nephrol. 2002. Vol. 13. P. 260–264.
27. Sheng Z., Guo-Ping W., Cong L., Muxiang Z. Eukaryotic initiation factor 4E (eIF4E) and angiogenesis:prognostic markers for breast cancer // BMC Cancer. 2006. Vol. 6. P. 231–243.
28. Smith K., Bateman A., Fussell H. et al. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis // Eur. J. Immunogenet. 2004. Vol. 31. P. 167–173.
Review
For citations:
Shevchenko A.V., Konenkov V.I., Babyshkina N.N., Savenkova O.V., Slonimskaya E.M. ANALYSIS OF ASSOCIATIONS OF VEGF-A GENE POLYMORPHISM AT POSITIONS 2578A/C AND +936C/T WITH DIFFERENT RECEPTOR STATUS IN BREAST CANCER PATIENTS. Siberian journal of oncology. 2013;(1):32-37. (In Russ.)
Views:
561
Email this article 
